Cerenome Taps XiFin for AI-Driven Revenue Cycle Management — Plus Therapeutics, Inc.

Event summary

Cerenome's CNSide Diagnostics selected XiFin Empower RCM for billing and clearinghouse services.
Implementation expected to begin in Q3 2026, including backlog submission.
XiFin platform offers scalable, automated infrastructure for higher test volumes with lower administrative costs.
Selection follows recent expansion of contracted payer coverage for CNSide® CSF Assay Platform.

The big picture

Cerenome's partnership with XiFin underscores the growing importance of AI-driven revenue cycle management in diagnostic services. The move comes as Cerenome expands its payer coverage, positioning itself to convert testing volume into cash collections more efficiently. This strategic alignment aims to improve operational efficiency and profitability in a competitive diagnostics market.

What we're watching

Execution Risk: How quickly Cerenome can integrate XiFin's platform and begin billing, including the backlog.
Revenue Growth: Whether the automated RCM infrastructure will improve clean claim rates and shorten days sales outstanding.
Market Expansion: The pace at which Cerenome can scale test volumes with the new billing infrastructure in place.